Patenting Compounds, Compositions, and Methods for Viral Infections: Patent Eligibility Considerations and Challenges

Dr. Longsworth is a director in the firm's Biotechnology & Chemical Practice. She is sought out by innovator and generic pharmaceutical companies world-wide for her insights and knowledge of intellectual property and Hatch-Waxman law. Dr. Longsworth counsels biopharmaceutical clients from around the world in all areas of patent procurement, including domestic and foreign patent preparation and lifecycle management strategies. She also counsels clients in IP due diligence evaluations for raising and investing in growth capital, executing strategic partnerships and M&A transactions, and going public. Dr. Longsworth practices primarily in the fields of biotherapeutics, small molecules, biologics, immunotherapy, antibody technologies, microbiome-based technologies, synthetic biology, DNA amplification/PCR, diagnostics, vaccines, viral vectors and drug delivery.

Mr. Sterne serves as an IP strategic advisor to start ups, emerging companies, and investors. He has authored some of the leading articles on board of director IP responsibility and the chief intellectual property officer. And over the years, his extensive practice has grown to include handling all phases of patent practice, including USPTO litigation, Federal Circuit and Supreme Court appeals, litigation in the district courts and the United States International Trade Commission (ITC), as well as patent licensing and monetization. Mr. Sterne is one of the leading attorneys in the new PTAB proceedings; he and his firm are consistently those with the highest number of proceedings before the PTAB. Mr. Sterne extensively speaks, writes, and provides CLE training on leading-edge areas of IP including the new PTAB contested proceedings, and has delivered hundreds of speeches about the every changing IP landscape and its implications domestically and internationally for IP law, innovation, and economics.